This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Nichi-Iko Pharmaceutical Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Shingo Iwamoto

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	less than a year

Recente managementupdates

Recent updates

CEO

Shingo Iwamoto

less than a year

Tenure

Shingo Iwamoto serves as Representative Director & President at Nichi-Iko Pharmaceutical Co., Ltd. since 2023.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Shingo Iwamoto	Representative Director & President	less than a year	geen gegevens	geen gegevens
Shuji Ishida	Managing Executive Officer & Director	less than a year	geen gegevens	0% ¥ 0
Hiroshi Shimazaki	Senior Executive Officer & Head of Quality Assurance & Pharmacovigilance Division	no data	geen gegevens	geen gegevens
Takashi Kashiwagi	Senior Executive Officer & Head of Corporate Strategy & Planning Division	no data	geen gegevens	geen gegevens
Susumu Kanda	Managing Executive Officer & Director	less than a year	geen gegevens	geen gegevens
Hirotoshi Naruse	Managing Executive Officer & Director	less than a year	geen gegevens	0% ¥ 0
Atsushi Matsumoto	Senior Executive Officer	no data	geen gegevens	geen gegevens
Tadashi Kojima	Senior Executive Officer	no data	geen gegevens	geen gegevens
Toru Furukawa	Senior Executive Officer	no data	geen gegevens	geen gegevens
Osamu Mihara	Director & Senior Managing Executive Officer	less than a year	geen gegevens	0% ¥ 0
Atsushi Kosugi	Senior Executive Officer	no data	geen gegevens	geen gegevens
Peter Kaemmerer	Chief Executive Officer of Sagent Pharmaceuticals	no data	geen gegevens	geen gegevens

0.8yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 4541 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Shingo Iwamoto	Representative Director & President	less than a year	geen gegevens	geen gegevens
Shuji Ishida	Managing Executive Officer & Director	no data	geen gegevens	0% ¥ 0
Susumu Kanda	Managing Executive Officer & Director	less than a year	geen gegevens	geen gegevens
Hirotoshi Naruse	Managing Executive Officer & Director	no data	geen gegevens	0% ¥ 0
Osamu Mihara	Director & Senior Managing Executive Officer	no data	geen gegevens	0% ¥ 0
Kenji Akane	Executive VP & Director	14.1yrs	geen gegevens	0% ¥ 0

0.8yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 4541 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.8 jaar), wat duidt op een nieuw bestuur.

This company listing is no longer active

Nichi-Iko Pharmaceutical Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Less than half of directors are independent

Nichi-Iko Pharmaceutical Co., Ltd., Annual General Meeting, Jun 30, 2022

Recent updates

Third quarter 2023 earnings released: JP¥232 loss per share (vs JP¥15.76 loss in 3Q 2022)

Nichi-Iko Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 14, 2023

Consensus forecasts updated

Less than half of directors are independent

Less than half of directors are independent

Nichi-Iko Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Nov 14, 2022

Consensus forecasts updated

Now 21% undervalued after recent price drop

First quarter 2023 earnings released: JP¥59.63 loss per share (vs JP¥58.89 loss in 1Q 2022)

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Nichi-Iko Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 12, 2022

Sawai Group Holdings Co., Ltd. and Nichi-Iko Pharmaceutical Co., Ltd. Announce Notice of Filing an Appeal in Patent Infringement Lawsuit Concerning Edirol Capsule

Tokyo District Court Renders Judgment on the Patent Infringement Lawsuit Concerning Edirol Capsules Against Sawai Pharmaceutical Co., Ltd. and Nichi-Iko Pharmaceutical Co., Ltd

Price target decreased to JP¥700

Full year 2022 earnings: EPS and revenues miss analyst expectations

Now 21% undervalued after recent price drop

Nichi-Iko Pharmaceutical Co., Ltd., Annual General Meeting, Jun 30, 2022

Consensus forecasts updated

Nichi-Iko Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 13, 2022

Nichi-Iko Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022

Tokyo District Court Renders Judgment on the Patent Infringement Lawsuit Concerning Edirol Capsules Against Sawai Pharmaceutical Co., Ltd., Nichi- Iko Pharmaceutical Co., Ltd. and Nissan Chemical Corporation

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to JP¥768

Nichi-Iko Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2022

Price target decreased to JP¥874

Second quarter 2022 earnings released: JP¥164 loss per share (vs JP¥2.25 loss in 2Q 2021)

Upcoming dividend of JP¥10.00 per share

Nichi-Iko Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Second Quarter and Fiscal Year Ending March 31, 2022

Nichi-Iko Pharmaceutical Co., Ltd. announced that it has received ¥5.23102 billion in funding from MediPal Holdings Corporation

Nichi-Iko Pharmaceutical Co., Ltd. announced that it expects to receive ¥5.23102 billion in funding from MediPal Holdings Corporation

Fuji Chemical Industries Co., Ltd. agreed to acquire Toyama No. 2 Factory of Nichi-Iko in Namerikawa City, Toyama Prefecture from Nichi-Iko Pharmaceutical Co., Ltd. (TSE:4541).

Full year 2021 earnings released: JP¥65.27 loss per share (vs JP¥80.41 profit in FY 2020)

Price target decreased to JP¥962

Full year 2021 earnings released: JP¥65.27 loss per share (vs JP¥80.41 profit in FY 2020)

Mitani Sangyo Co., Ltd. (TSE:8285) agreed to acquire remaining 49% stake in Active Pharma Co., Ltd. from Nichi-Iko Pharmaceutical Co., Ltd. (TSE:4541).

Upcoming dividend of JP¥15.00 per share

New 90-day high: JP¥1,106

Chugai Pharmaceutical Co., Ltd. Refiles Patent Infringement Lawsuit Concerning Edirol Capsules

Third quarter 2021 earnings released: JP¥5.65 loss per share (vs JP¥39.40 profit in 3Q 2020)

Revenue and earnings miss expectations

Nichi-Iko Pharmaceutical Co., Ltd. (TSE:4541) acquired Generics and Takayama Plane related Businesses from Teva Takeda Pharma Ltd.

Nichi-Iko Pharmaceutical Co., Ltd. to Report Q3, 2021 Results on Feb 10, 2021

New 90-day low: JP¥994

New 90-day low: JP¥997

Chugai Pharmaceutical Co., Ltd. Files Patent Infringement Lawsuit Against Nissan Chemical Corporation, Sawai Pharmaceutical Co., Ltd. and Nichi-Iko Pharmaceutical Co., Ltd

Nichi-Iko Pharmaceutical Co., Ltd. to Report Q2, 2021 Results on Nov 11, 2020

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd